A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Terminated
CT.gov ID
NCT03135262
Collaborator
(none)
29
21
4
34.5
1.4
0

Study Details

Study Description

Brief Summary

This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL and obinutuzumab or rituximab in combination with idasanutlin and venetoclax in participants with R/R DLBCL. The study will include an initial dose-escalation phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase II doses (RP2Ds) and regimen for idasanutlin and venetoclax in combination with obinutuzumab for FL participants and in combination with rituximab for DLBCL participants.

Study Design

Study Type:
Interventional
Actual Enrollment :
29 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Actual Study Start Date :
Jun 15, 2017
Actual Primary Completion Date :
Apr 30, 2020
Actual Study Completion Date :
Apr 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dose-Escalation Cohort: FL

Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.

Drug: Idasanutlin
Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Obinutuzumab
Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).

Drug: Venetoclax
Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Experimental: Dose-Escalation Cohort: DLBCL

Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.

Drug: Idasanutlin
Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Obinutuzumab
Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).

Drug: Venetoclax
Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Rituximab
Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.

Experimental: Expansion Cohort: FL

Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.

Drug: Idasanutlin
Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Obinutuzumab
Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).

Drug: Venetoclax
Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Experimental: Expansion Cohort: DLBCL

Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.

Drug: Idasanutlin
Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Venetoclax
Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.

Drug: Rituximab
Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.

Outcome Measures

Primary Outcome Measures

  1. RP2D of Idasanutlin When Given in Combination With Obinutuzumab or Rituximab [Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)]

    It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. phases. The study was closed because at escalation doses 100 (in combination with venetoclax 400 mg) and 150 mg (in combination with venetoclax 200 mg) Idasanutlin, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The subpopulations of DLBCL and FL were showed no difference in their genetic subtype make-up, therefore, Cohorts Safety, 1, 2, 3 contain both populations. The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.

  2. RP2D of Venetoclax When Given in Combination With Obinutuzumab or Rituximab [Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)]

    It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. The study was closed because at escalation doses 200 (in combination with 150 mg idasanutlin) and 400 (in combination with 100 mg idasanutlin) mg Venetoclax, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.

  3. Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)]

    DLT is defined as any one of the following events occurring during first two Cycles of treatment and assessed by the investigator as clearly not related to patient's underlying disease: - Any Grade 5 adverse event (AE) unless unequivocally due to the underlying malignancy or extraneous causes; - AE of any grade that leads to a delay of more than 14 days at the start of next treatment cycle; - Hematologic AEs (neutropenia, thrombocytopenia); - Non-hematologic AE, except IRRs, laboratory TLS without manifestations of clinical TLS, AST or ALT, diarrhea, nausea or vomiting, fatigue, asthenia, anorexia, or constipation, hepatic transaminase.

  4. Percentage of Participants With Adverse Events (AEs) [From Baseline up to approximately 48 months]

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a casual relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

  5. Percentage of Participants With Complete Response (CR), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography-Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria [At end of Induction (EOI) (within 6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days])]

    The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I). Therefore the result data not derived and not reported.

Secondary Outcome Measures

  1. Percentage of Participants With CR, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based complete response (CR), which required a complete metabolic response with a score of 1, 2 or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [<=] mediastinum; 3 = uptake greater than [>] mediastinum and <= liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if intermediate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.

  2. Percentage of Participants With CR, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required to complete radiologic response with all of the following: target nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. Therefore the result data not derived and not reported.

  3. Percentage of Participants With CR, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion (LDi); no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who received at least 2 cycles of Induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. This outcome measure therefore not derived and not reported.

  4. Percentage of Participants With Objective Response, Determined by the IRC on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The IRC was to evaluate responses at the end of induction treatment using Luagno 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2 or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Therefore the result data not derived and not reported. The study was pre-maturely terminated.

  5. Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The investigator was to evaluate responses at end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.

  6. Percentage of Participants With Objective Response, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/nomal, regressed, but no increase; and spleen must have regressed by >50% in length. Therefore the result data not derived and not reported. The study was pre-maturely terminated.

  7. Percentage of Participants With Objective Response at EOI, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria [At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]]

    The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.

  8. Percentage of Participants With Objective Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria [From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months]

    The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.

  9. Observed Serum Concentration of Obinutuzumab in Participants With FL [From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)]

    Observed Serum Concentration of Obinutuzumab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.

  10. Observed Serum Concentration of Obinutuzumab in Participants With DLBCL [Induction: Pre-dose (any time prior to dose on same day) and 30 min post-dose on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) and 30 min post-dose on Day 1 of Cycles 2, 4 and 6 (each cycle = 28 days)]

    Observed Serum Concentration of Obinutuzumab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

  11. Observed Serum Concentration of Rituximab in Participants With FL [Induction: Pre-dose (any time prior to dose on same day) on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) on Day 1 of Cycles 2, 4, 6; 30 min post-dose on Day 1 of Cycles 1 and 6 (each cycle = 28 days)]

    Observed Serum Concentration of Rituximab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

  12. Observed Serum Concentration of Rituximab in Participants With DLBCL [From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)]

    Observed Serum Concentration of Rituximab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

  13. Observed Plasma Concentration of Idasanutlin in Participants With FL [From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)]

    Observed Plasma Concentration of Idasanutlin in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported

  14. Observed Plasma Concentration of Idasanutlin in Participants With DLBCL [From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)]

    Observed Plasma Concentration of Idasanutlin in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported

  15. Observed Plasma Concentration of Venetoclax in Participants With FL [From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)]

    Observed Plasma Concentration of Venetoclax in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.

  16. Observed Plasma Concentration of Venetoclax in Participants With DLBCL [From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)]

    Observed Plasma Concentration of Venetoclax in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

  • B-cell lymphoma classified as either of the following: R/R FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cluster of differentiation 20 (CD20) monoclonal antibody; R/R DLBCL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody in participants who are not eligible for second line combination chemotherapy and autologous stem-cell transplantation, have failed second line combination chemotherapy, or experienced disease progression following autologous stem-cell transplantation

  • Histologically documented CD20-positive lymphoma

  • Fluorodeoxyglucose (FDG)-avid lymphoma (that is [i.e.], PET-positive lymphoma)

  • At least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or magnetic resonance imaging [MRI])

  • Availability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL or DLBCL

Exclusion Criteria:
  • Known CD20-negative status at relapse or progression

  • Prior allogeneic stem-cell transplantation (SCT)

  • Completion of autologous SCT within 100 days prior to Day 1 of Cycle 1

  • Prior standard or investigational anti-cancer therapy as specified: Radioimmunoconjugate within 12 weeks prior to Day 1 of Cycle 1; Monoclonal antibody or antibody-drug conjugate within 4 weeks prior to Day 1 of Cycle 1; Radiotherapy, chemotherapy, hormonal therapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1

  • Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade less than or equal to (</=) 2 (according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) prior to Day 1 of Cycle 1

  • Grade 3b FL

  • History of transformation of indolent disease to DLBCL (expansion-phase only)

  • Central nervous system lymphoma or leptomeningeal infiltration

  • Treatment with systemic corticosteroids >20 mg/day, prednisone or equivalent

  • Clinical conditions requiring treatment with oral or parenteral anticoagulants or antiplatelet agents unless treatment can be discontinued 7 days (or 5 half-lives) prior to initiation of study treatment (except used as flushes for indwelling catheters)

  • History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies

  • Known hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulation

  • Current or history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection: positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (HBcAb), or HCV antibody at screening

  • History of progressive multifocal leukoencephalopathy (PML)

  • History of other malignancy that could affect compliance with the protocol or interpretation of results

  • Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results

  • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by study treatment, such as severe hereditary coagulation disorders or insulin-dependent diabetes mellitus that is not optimally controlled with medical management (example, presence of ketoacidosis)

  • Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, or anticipation of a major surgical procedure during the study

  • Inadequate hematologic function (unless due to underlying lymphoma), defined as follows: Hemoglobin less than (<) 9 grams per decilitre (g/dL), absolute neutrophil count (ANC) <1.510^9 cells per liter (cells/L), platelet count <7510^9 cells/L

  • Any of the following abnormal laboratory values (unless due to underlying lymphoma): International normalized ratio (INR) or prothrombin time (PT) >1.5upper limit of normal (ULN) in the absence of therapeutic anticoagulation; partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) >1.5ULN in the absence of a lupus anticoagulant

  • Life expectancy <3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Colorado Aurora Colorado United States 80045-2517
2 The University of Chicago Medical Center Chicago Illinois United States 60637
3 Norton Cancer Institute - Dutchmans Louisville Kentucky United States 40207
4 Mount Sinai Medical Center New York New York United States 10029
5 Allegheny General Hospital Pittsburgh Pennsylvania United States 15212
6 Guthrie Clinic Sayre Pennsylvania United States 18840
7 Swedish Cancer Inst. Seattle Washington United States 98104
8 Prince of Wales Hospital Randwick New South Wales Australia 2031
9 Westmead Hospital Westmead New South Wales Australia 2145
10 Linear Clinical Research Limited Nedlands Western Australia Australia 6009
11 Klinikum Augsburg Augsburg Germany 86156
12 Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden Dresden Germany 01307
13 SLK-Kliniken Heilbronn GmbH Heilbronn Germany 74078
14 Klinikum rechts der Isar der TU München München Germany 81675
15 Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie Würzburg Germany 97080
16 Keimyung University Dongsan Medical Center Daegu Korea, Republic of 41931
17 Severance Hospital Seoul Korea, Republic of 03722
18 Asan Medical Center Seoul Korea, Republic of 05505
19 Samsung Medical Center Seoul Korea, Republic of 06351
20 Christchurch Hospital Christchurch New Zealand 8011
21 Auckland Clinical Studies Limited Grafton New Zealand 1010

Sponsors and Collaborators

  • Hoffmann-La Roche

Investigators

  • Study Director: Clinical Trials, Hoffmann-La Roche

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT03135262
Other Study ID Numbers:
  • BH39147
  • 2016-002480-34
First Posted:
May 1, 2017
Last Update Posted:
Dec 7, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details 29 Participants (ITT population) were enrolled at 13 sites in the USA, Australia, South Korea, New Zealand and Germany during the dose escalation phase. 1 participant was undefined as the diagnosis at study entry was not provided. Due to the study's pre-mature termination, the planned Dose Expansion Phase did not take place for both arms DLBCL and FL.
Pre-assignment Detail The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase. In each DLBCL and FL arm, participants are in Safety Cohort, Cohort 1, Cohort 2, Cohort 3 and Cohort 3- Not defined (DLBCL only). All Adverse Events are reported per Cohort rather than per Arm.
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Period Title: Overall Study
STARTED 9 6 7 6 1
COMPLETED 0 0 0 0 0
NOT COMPLETED 9 6 7 6 1

Baseline Characteristics

Arm/Group Title Dose-Escalation DLBCL and FL Safety Cohort Dose-Escalation DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3 Total
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg Total of all reporting groups
Overall Participants 9 6 7 6 1 29
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]
58.6
(15.5)
68.5
(8.7)
72.4
(8.6)
74.3
(5.5)
25.0
(0)
66.1
(14.4)
Sex: Female, Male (Count of Participants)
Female
3
33.3%
3
50%
3
42.9%
3
50%
0
0%
12
41.4%
Male
6
66.7%
3
50%
4
57.1%
3
50%
1
100%
17
58.6%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Not Hispanic or Latino
9
100%
6
100%
7
100%
6
100%
1
100%
29
100%
Unknown or Not Reported
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Asian
2
22.2%
0
0%
1
14.3%
2
33.3%
0
0%
5
17.2%
Native Hawaiian or Other Pacific Islander
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Black or African American
0
0%
0
0%
0
0%
1
16.7%
0
0%
1
3.4%
White
7
77.8%
5
83.3%
6
85.7%
2
33.3%
1
100%
21
72.4%
More than one race
0
0%
1
16.7%
0
0%
1
16.7%
0
0%
2
6.9%
Unknown or Not Reported
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%

Outcome Measures

1. Primary Outcome
Title RP2D of Idasanutlin When Given in Combination With Obinutuzumab or Rituximab
Description It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. phases. The study was closed because at escalation doses 100 (in combination with venetoclax 400 mg) and 150 mg (in combination with venetoclax 200 mg) Idasanutlin, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The subpopulations of DLBCL and FL were showed no difference in their genetic subtype make-up, therefore, Cohorts Safety, 1, 2, 3 contain both populations. The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.
Time Frame Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Outcome Measure Data

Analysis Population Description
Safety Population
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escaltion DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number [mg]
NA
NA
150
NA
NA
2. Primary Outcome
Title RP2D of Venetoclax When Given in Combination With Obinutuzumab or Rituximab
Description It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. The study was closed because at escalation doses 200 (in combination with 150 mg idasanutlin) and 400 (in combination with 100 mg idasanutlin) mg Venetoclax, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.
Time Frame Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Outcome Measure Data

Analysis Population Description
Safety Population
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number [mg]
NA
NA
200
NA
NA
3. Primary Outcome
Title Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Description DLT is defined as any one of the following events occurring during first two Cycles of treatment and assessed by the investigator as clearly not related to patient's underlying disease: - Any Grade 5 adverse event (AE) unless unequivocally due to the underlying malignancy or extraneous causes; - AE of any grade that leads to a delay of more than 14 days at the start of next treatment cycle; - Hematologic AEs (neutropenia, thrombocytopenia); - Non-hematologic AE, except IRRs, laboratory TLS without manifestations of clinical TLS, AST or ALT, diarrhea, nausea or vomiting, fatigue, asthenia, anorexia, or constipation, hepatic transaminase.
Time Frame Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Outcome Measure Data

Analysis Population Description
Safety-Evaluable Patients
Arm/Group Title Dose Escaltion DLBCL and FL Safety Cohort Dose Escaltion DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number [Percentage of Participants]
0
0%
16.7
278.3%
28.6
408.6%
16.7
278.3%
0
0%
4. Primary Outcome
Title Percentage of Participants With Adverse Events (AEs)
Description An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a casual relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time Frame From Baseline up to approximately 48 months

Outcome Measure Data

Analysis Population Description
Safety Population
Arm/Group Title Dose Escaltion DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number [Percentage of Participants]
100
1111.1%
100
1666.7%
100
1428.6%
100
1666.7%
0
0%
5. Primary Outcome
Title Percentage of Participants With Complete Response (CR), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography-Computed Tomography (PET-CT) Scans Using Modified Lugano 2014 Criteria
Description The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I). Therefore the result data not derived and not reported.
Time Frame At end of Induction (EOI) (within 6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days])

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose-Escalation DLBCL and FL Safety Cohort Dose-Escalation DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
6. Secondary Outcome
Title Percentage of Participants With CR, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria
Description The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based complete response (CR), which required a complete metabolic response with a score of 1, 2 or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [<=] mediastinum; 3 = uptake greater than [>] mediastinum and <= liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if intermediate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
ITT Population; exploratory analysis of the dose escalation phase (Part I). The study plan was for efficacy analyses to be based on responses in participants enrolled during the expansion phase (Part II), but it was not opened (i.e., no enrollment) and at the study was terminated early.
Arm/Group Title Dose Escaltion DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number (90% Confidence Interval) [Percentage of Participants]
22.2
246.7%
16.7
278.3%
28.6
408.6%
16.7
278.3%
0
0%
7. Secondary Outcome
Title Percentage of Participants With CR, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria
Description The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required to complete radiologic response with all of the following: target nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. Therefore the result data not derived and not reported.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e. , no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escaltion DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
8. Secondary Outcome
Title Percentage of Participants With CR, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria
Description The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion (LDi); no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who received at least 2 cycles of Induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. This outcome measure therefore not derived and not reported.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
ITT Population; exploratory analysis of the dose escalation phase (Part I). The study plan was for efficacy analyses to be based on responses in participants enrolled during expansion phase (Part II), but it was not opened (i.e., no enrollment) and at the study was terminated early.
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
9. Secondary Outcome
Title Percentage of Participants With Objective Response, Determined by the IRC on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria
Description The IRC was to evaluate responses at the end of induction treatment using Luagno 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2 or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Therefore the result data not derived and not reported. The study was pre-maturely terminated.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escaltion DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
10. Secondary Outcome
Title Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria
Description The investigator was to evaluate responses at end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
ITT Population
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 9 6 7 6 1
Number (90% Confidence Interval) [Percentage of Participants]
33.3
370%
16.7
278.3%
28.6
408.6%
33.3
555%
0
0%
11. Secondary Outcome
Title Percentage of Participants With Objective Response, Determined by the IRC on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria
Description The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/nomal, regressed, but no increase; and spleen must have regressed by >50% in length. Therefore the result data not derived and not reported. The study was pre-maturely terminated.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
12. Secondary Outcome
Title Percentage of Participants With Objective Response at EOI, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria
Description The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.
Time Frame At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
13. Secondary Outcome
Title Percentage of Participants With Objective Response During the Study, Determined by the Investigator on the Basis of CT Scans Alone Using Modified Lugano 2014 Criteria
Description The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.
Time Frame From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months

Outcome Measure Data

Analysis Population Description
The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
14. Secondary Outcome
Title Observed Serum Concentration of Obinutuzumab in Participants With FL
Description Observed Serum Concentration of Obinutuzumab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported. The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.
Time Frame From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation FL Safety Cohort Dose Escalation FL Cohort 1 Dose Escalation FL Cohort 2 Dose Escalation FL Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0
15. Secondary Outcome
Title Observed Serum Concentration of Obinutuzumab in Participants With DLBCL
Description Observed Serum Concentration of Obinutuzumab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.
Time Frame Induction: Pre-dose (any time prior to dose on same day) and 30 min post-dose on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) and 30 min post-dose on Day 1 of Cycles 2, 4 and 6 (each cycle = 28 days)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation DLBCL Safety Cohort 2 Dose Escalation DLBCL Cohort 1 Dose Escaltion DLBCL Cohort 2 Dose Escalation DLBCL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
16. Secondary Outcome
Title Observed Serum Concentration of Rituximab in Participants With FL
Description Observed Serum Concentration of Rituximab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.
Time Frame Induction: Pre-dose (any time prior to dose on same day) on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) on Day 1 of Cycles 2, 4, 6; 30 min post-dose on Day 1 of Cycles 1 and 6 (each cycle = 28 days)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation FL Safety Cohort Dose Escalation FL Cohort 1 Dose Escalation FL Cohort 2 Dose Escalation FL Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0
17. Secondary Outcome
Title Observed Serum Concentration of Rituximab in Participants With DLBCL
Description Observed Serum Concentration of Rituximab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.
Time Frame From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escaltion DLBCL Safety Cohort Dose Escalation DLBCL Cohort 1 Dose Escaltion DLBCL Cohort 2 Dose Escalation DLBCL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
18. Secondary Outcome
Title Observed Plasma Concentration of Idasanutlin in Participants With FL
Description Observed Plasma Concentration of Idasanutlin in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported
Time Frame From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation FL Safety Cohort Dose Escalation FL Cohort 1 Dose Escalation FL Cohort 2 Dose Escalation FL Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0
19. Secondary Outcome
Title Observed Plasma Concentration of Idasanutlin in Participants With DLBCL
Description Observed Plasma Concentration of Idasanutlin in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported
Time Frame From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation DLBCL Safety Cohort Dose Escalation DLBCL Cohort 1 Dose Escaltion DLBCL Cohort 2 Dose Escalation DLBCL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0
20. Secondary Outcome
Title Observed Plasma Concentration of Venetoclax in Participants With FL
Description Observed Plasma Concentration of Venetoclax in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.
Time Frame From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escalation FL Safety Cohort Dose Escalation FL Cohort 1 Dose Escalation FL Cohort 2 Dose Escalation FL Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0
21. Secondary Outcome
Title Observed Plasma Concentration of Venetoclax in Participants With DLBCL
Description Observed Plasma Concentration of Venetoclax in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place. The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.
Time Frame From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Outcome Measure Data

Analysis Population Description
ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.
Arm/Group Title Dose Escaltion DLBCL Safety Cohort Dose Escaltion DLBCL Cohort 1 Dose Escalation DLBCL Cohort 2 Dose Escalation DLBCL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Measure Participants 0 0 0 0 0

Adverse Events

Time Frame From Baseline Up to Approximately 3 Years
Adverse Event Reporting Description Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Arm/Group Title Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Arm/Group Description Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
All Cause Mortality
Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 6/9 (66.7%) 2/6 (33.3%) 2/7 (28.6%) 2/6 (33.3%) 0/1 (0%)
Serious Adverse Events
Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 3/9 (33.3%) 3/6 (50%) 4/7 (57.1%) 4/6 (66.7%) 0/1 (0%)
Blood and lymphatic system disorders
NEUTROPENIA 1/9 (11.1%) 2 0/6 (0%) 0 1/7 (14.3%) 1 1/6 (16.7%) 1 0/1 (0%) 0
THROMBOCYTOPENIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 0/1 (0%) 0
Gastrointestinal disorders
ABDOMINAL PAIN 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
UPPER GASTROINTESTINAL HAEMORRHAGE 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
General disorders
NON-CARDIAC CHEST PAIN 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
PYREXIA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Hepatobiliary disorders
CHOLECYSTITIS 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
HYPERBILIRUBINAEMIA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Infections and infestations
DEVICE RELATED INFECTION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 0/1 (0%) 0
PNEUMONIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 0/1 (0%) 0
UPPER RESPIRATORY TRACT INFECTION 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Injury, poisoning and procedural complications
INFUSION RELATED REACTION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Investigations
ALANINE AMINOTRANSFERASE INCREASED 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
TRANSAMINASES INCREASED 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Nervous system disorders
HEADACHE 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
SYNCOPE 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 0/1 (0%) 0
Other (Not Including Serious) Adverse Events
Dose Escalation DLBCL and FL Safety Cohort Dose Escalation DLBCL and FL Cohort 1 Dose Escalation DLBCL and FL Cohort 2 Dose Escalation DLBCL and FL Cohort 3 Not Defined for DLBCL or FL Subgroups Cohort 3
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 9/9 (100%) 6/6 (100%) 7/7 (100%) 6/6 (100%) 0/1 (0%)
Blood and lymphatic system disorders
ANAEMIA 4/9 (44.4%) 5 1/6 (16.7%) 1 4/7 (57.1%) 4 3/6 (50%) 6 3/1 (300%) 6
LEUKOPENIA 3/9 (33.3%) 3 1/6 (16.7%) 1 3/7 (42.9%) 8 1/6 (16.7%) 1 1/1 (100%) 1
LYMPHOPENIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 2/6 (33.3%) 2 2/1 (200%) 2
NEUTROPENIA 7/9 (77.8%) 13 5/6 (83.3%) 8 7/7 (100%) 20 5/6 (83.3%) 21 5/1 (500%) 21
THROMBOCYTOPENIA 7/9 (77.8%) 9 4/6 (66.7%) 5 7/7 (100%) 13 5/6 (83.3%) 6 5/1 (500%) 6
Cardiac disorders
ATRIAL FIBRILLATION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
Endocrine disorders
HYPERTHYROIDISM 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
Eye disorders
EYE DISORDER 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
EYE PAIN 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PHOTOPHOBIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
VISION BLURRED 1/9 (11.1%) 1 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Gastrointestinal disorders
ABDOMINAL DISCOMFORT 0/9 (0%) 0 1/6 (16.7%) 1 1/7 (14.3%) 2 0/6 (0%) 0 0/1 (0%) 0
ABDOMINAL PAIN 3/9 (33.3%) 3 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
ANAL INCONTINENCE 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
CONSTIPATION 2/9 (22.2%) 2 1/6 (16.7%) 1 0/7 (0%) 0 2/6 (33.3%) 2 2/1 (200%) 2
DIARRHOEA 5/9 (55.6%) 9 3/6 (50%) 3 4/7 (57.1%) 6 4/6 (66.7%) 10 4/1 (400%) 10
DYSPEPSIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 2 1/1 (100%) 2
FLATULENCE 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
GASTROOESOPHAGEAL REFLUX DISEASE 3/9 (33.3%) 3 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
MOUTH ULCERATION 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
NAUSEA 6/9 (66.7%) 14 4/6 (66.7%) 6 3/7 (42.9%) 3 3/6 (50%) 8 3/1 (300%) 8
ODYNOPHAGIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
STOMATITIS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
TONGUE HAEMATOMA 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 2 0/6 (0%) 0 0/1 (0%) 0
VOMITING 3/9 (33.3%) 5 3/6 (50%) 3 1/7 (14.3%) 1 2/6 (33.3%) 2 2/1 (200%) 2
General disorders
CHEST PAIN 0/9 (0%) 0 3/6 (50%) 3 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
CHILLS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
FATIGUE 1/9 (11.1%) 1 3/6 (50%) 3 3/7 (42.9%) 3 1/6 (16.7%) 1 1/1 (100%) 1
NON-CARDIAC CHEST PAIN 1/9 (11.1%) 2 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
OEDEMA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PAIN 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PYREXIA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
UNEVALUABLE EVENT 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
Infections and infestations
CELLULITIS 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
CLOSTRIDIUM DIFFICILE COLITIS 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
GASTROENTERITIS 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
GASTROENTERITIS NOROVIRUS 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HERPES ZOSTER 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 1/6 (16.7%) 1 1/1 (100%) 1
INFECTION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
MUCOSAL INFECTION 1/9 (11.1%) 1 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
ORAL CANDIDIASIS 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
RESPIRATORY TRACT INFECTION 1/9 (11.1%) 3 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
SINUSITIS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
UPPER RESPIRATORY TRACT INFECTION 3/9 (33.3%) 4 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
WOUND INFECTION 0/9 (0%) 0 1/6 (16.7%) 2 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Injury, poisoning and procedural complications
ACCIDENTAL OVERDOSE 0/9 (0%) 0 1/6 (16.7%) 4 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
CONTUSION 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
INFUSION RELATED REACTION 3/9 (33.3%) 3 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
MEDICATION ERROR 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
PRODUCT ADMINISTRATION ERROR 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
PRODUCT DOSE OMISSION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
SKIN ABRASION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
WOUND COMPLICATION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
Investigations
ALANINE AMINOTRANSFERASE 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
ALANINE AMINOTRANSFERASE INCREASED 1/9 (11.1%) 1 0/6 (0%) 0 1/7 (14.3%) 2 0/6 (0%) 0 0/1 (0%) 0
AMYLASE INCREASED 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
ASPARTATE AMINOTRANSFERASE INCREASED 2/9 (22.2%) 3 0/6 (0%) 0 1/7 (14.3%) 1 1/6 (16.7%) 1 1/1 (100%) 1
BLOOD ALKALINE PHOSPHATASE INCREASED 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
BLOOD BILIRUBIN INCREASED 1/9 (11.1%) 1 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
LYMPHOCYTE COUNT DECREASED 1/9 (11.1%) 3 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
NEUTROPHIL COUNT DECREASED 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 3 1/1 (100%) 3
PLATELET COUNT DECREASED 1/9 (11.1%) 4 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
RESPIROVIRUS TEST POSITIVE 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
SERUM FERRITIN INCREASED 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
WEIGHT DECREASED 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
WHITE BLOOD CELL COUNT DECREASED 1/9 (11.1%) 4 0/6 (0%) 0 1/7 (14.3%) 5 2/6 (33.3%) 7 2/1 (200%) 7
Metabolism and nutrition disorders
DECREASED APPETITE 1/9 (11.1%) 1 1/6 (16.7%) 1 2/7 (28.6%) 2 0/6 (0%) 0 0/1 (0%) 0
DIABETES MELLITUS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
GOUT 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
HYPERCALCAEMIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HYPERGLYCAEMIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
HYPOALBUMINAEMIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
HYPOCALCAEMIA 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
HYPOKALAEMIA 1/9 (11.1%) 1 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HYPOMAGNESAEMIA 2/9 (22.2%) 2 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HYPONATRAEMIA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HYPOPHAGIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
TUMOUR LYSIS SYNDROME 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Musculoskeletal and connective tissue disorders
ARTHRALGIA 1/9 (11.1%) 3 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
BACK PAIN 0/9 (0%) 0 0/6 (0%) 0 2/7 (28.6%) 2 0/6 (0%) 0 0/1 (0%) 0
BONE PAIN 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
FLANK PAIN 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
JOINT STIFFNESS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
MUSCULOSKELETAL PAIN 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
MYALGIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PAIN IN EXTREMITY 2/9 (22.2%) 4 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
SPINAL OSTEOARTHRITIS 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
VERTEBRAL FORAMINAL STENOSIS 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
Nervous system disorders
DIZZINESS 2/9 (22.2%) 4 1/6 (16.7%) 1 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
HEADACHE 3/9 (33.3%) 5 1/6 (16.7%) 2 2/7 (28.6%) 2 1/6 (16.7%) 1 1/1 (100%) 1
NEURALGIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
NEUROPATHY PERIPHERAL 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PARAESTHESIA 1/9 (11.1%) 1 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
RADICULAR PAIN 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
SYNCOPE 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
TRANSIENT ISCHAEMIC ATTACK 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Psychiatric disorders
ANXIETY 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
DELIRIUM 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
DEPRESSION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
INSOMNIA 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Renal and urinary disorders
ACUTE KIDNEY INJURY 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
DYSURIA 1/9 (11.1%) 2 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
HAEMATURIA 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
MICTURITION URGENCY 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
URINARY RETENTION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Respiratory, thoracic and mediastinal disorders
COUGH 2/9 (22.2%) 2 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
DYSPNOEA EXERTIONAL 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
EPISTAXIS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
LOWER RESPIRATORY TRACT CONGESTION 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
NASAL CONGESTION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
PRODUCTIVE COUGH 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
Skin and subcutaneous tissue disorders
ERYTHEMA 0/9 (0%) 0 1/6 (16.7%) 1 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
ERYTHEMA AB IGNE 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
HYPERHIDROSIS 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
NIGHT SWEATS 1/9 (11.1%) 2 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
PAIN OF SKIN 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
RASH 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 2 1/1 (100%) 2
RASH MACULO-PAPULAR 1/9 (11.1%) 1 0/6 (0%) 0 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
Vascular disorders
DEEP VEIN THROMBOSIS 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
FLUSHING 1/9 (11.1%) 1 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
HYPOTENSION 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1
LYMPHATIC FISTULA 0/9 (0%) 0 0/6 (0%) 0 1/7 (14.3%) 1 0/6 (0%) 0 0/1 (0%) 0
ORTHOSTATIC HYPOTENSION 0/9 (0%) 0 1/6 (16.7%) 1 0/7 (0%) 0 0/6 (0%) 0 0/1 (0%) 0
THROMBOPHLEBITIS SUPERFICIAL 0/9 (0%) 0 0/6 (0%) 0 0/7 (0%) 0 1/6 (16.7%) 1 1/1 (100%) 1

Limitations/Caveats

Dose expansion part of the study did not take place. AEs were not differentiated for DLBCL and FL arms since these are sub mutations of disease which does nor show differences in AEs.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact

Name/Title Reference Study ID Number: BH39147
Organization www.roche.com/about_roche/roche_worldwide.htm
Phone 888-662-6728 (U.S. Only)
Email global-roche-genentech-trials@gene.com
Responsible Party:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT03135262
Other Study ID Numbers:
  • BH39147
  • 2016-002480-34
First Posted:
May 1, 2017
Last Update Posted:
Dec 7, 2021
Last Verified:
Dec 1, 2021